Originally published by our sister publication Clinical Oncology News
The FDA granted accelerated approval for glofitamab-gxbm (Columvi, Genentech) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of